Humanigen Inc. (HGEN) Announces NIH Advances ACTIV-5/BET-B Trial Evaluating Lenzilumab from a Phase 2 Exploratory Study to a Phase 2/3 Study for the Treatment of COVID-19
Go back to Humanigen Inc. (HGEN) Announces NIH Advances ACTIV-5/BET-B Trial Evaluating Lenzilumab from a Phase 2 Exploratory Study to a Phase 2/3 Study for the Treatment of COVID-19| Central Hudson Gas & Electric 4.5% Cumulative Preferred Stock (NASDAQ: HGEN) | Delayed: 0.04 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.04 | 52 Week High | $4.00 | |||
| Open | $0.04 | 52 Week Low | $4.00 | |||
| Day High | $0.04 | P/E | N/A | |||
| Day Low | $0.04 | EPS | $0.00 | |||
| Volume | 3,829 | |||||
